Anavex Strengthens Alzheimer’s Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property

Preclinical Data Presented at 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy New York, NY — March 31, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types of cancer,…